ライフサイエンスコーパス: delayed hypersensitivity

1 stimulated with OVA (assay for induction of delayed hypersensitivity).

2 ir recipients failed to display RPE-specific delayed hypersensitivity.

3 owed the capacity to suppress donor-specific delayed hypersensitivity.

4 roinflammatory Th1 cells in a mouse model of delayed hypersensitivity.

5 with spleen cells that suppress RPE-specific delayed hypersensitivity and autoimmune rejection.

6 The absence of systemic delayed hypersensitivity and complement-fixing Abs in th

7 ere tested for suppression of DBA/2-specific delayed hypersensitivity and concomitant immunity.

8 . into naive recipients induced allospecific delayed hypersensitivity and elicited delayed hypersensi

9 e recipients were evaluated for RPE-specific delayed hypersensitivity and examined clinically and his

10 a2 induce immune deviation in vivo (impaired delayed hypersensitivity and IgG2a Ab production) when i

11 these types of grafts display donor-specific delayed hypersensitivity and in vitro proliferating prim

12 1 is functionally relevant in the genesis of delayed hypersensitivity and may be a useful therapeutic

13 f IFN-gamma, induce macrophage cytotoxicity, delayed hypersensitivity, and enhanced cellular immunity

14 Th1 cells, which mediate delayed hypersensitivity, are the polar opposites of CD4

15 Ag-specific proliferation and delayed hypersensitivity, as well as mitogen-induced IFN

16 geneic mice elicited an intense RPE-specific delayed hypersensitivity associated with a vehement cell

17 binding proteins inhibit local expression of delayed hypersensitivity by a T-cell fibronectin-depende

18 stered therapeutically to animals undergoing delayed hypersensitivity can almost completely abolish T

19 fragments were evaluated for donor-specific delayed hypersensitivity (DH) and ACAID, and fragment-co

20 recipients were evaluated for acquisition of delayed hypersensitivity (DH) and cytotoxic T cells (Tc)

21 opulations of regulatory T cells that impair delayed hypersensitivity (DH) by two different mechanism

22 lenic CD8+ effector cells which downregulate delayed hypersensitivity (DH) in immunized mice.

23 Acquisition of donor-specific delayed hypersensitivity (DH) was also assessed in recip

24 ologically and acquisition of donor-specific delayed hypersensitivity (DH) was assessed at selected i

25 Ovalbumin (OVA)-specific delayed hypersensitivity (DH) was not impaired when OVA

26 nduces an Ag-specific impairment of systemic delayed hypersensitivity (DH), termed anterior chamber a

27 n (ACAID), is characterized by impairment of delayed hypersensitivity (DH).

28 urans can result in either immediate (IH) or delayed hypersensitivity (DH).

29 sitize recipient mice to donor alloantigens (delayed hypersensitivity, DH) was evaluated.

30 ecific delayed hypersensitivity and elicited delayed hypersensitivity directed at alloantigens.

31 (a) of T-cell activation in vitro and (b) of delayed hypersensitivity expression in vivo.

32 ear pinnae of normal BALB/c mice (assay for delayed hypersensitivity expression) or coinjected with

33 lar immune privilege, prevents Th1-dependent delayed hypersensitivity from developing in response to

34 ure TGFbeta and suppressed the expression of delayed hypersensitivity in a local adoptive transfer as

35 ed regulatory lymphoid cells that suppressed delayed hypersensitivity in naive recipients.

36 ulatory T cells that suppressed RPE-specific delayed hypersensitivity in naive syngeneic recipients.

37 ls in vitro and suppressed the expression of delayed hypersensitivity in vivo.

38 ess the induction and then the expression of delayed hypersensitivity in vivo.

39 we show that using a rat model of cutaneous delayed hypersensitivity, MCP-1 expression correlates sp

40 Three patients developed a delayed hypersensitivity reaction after vaccination.

41 nd findings suggest that HORV is caused by a delayed hypersensitivity reaction to vancomycin.

42 ction rate is high, and it was produced by a delayed hypersensitivity reaction with a Th2 response.

43 through an indirect mechanism similar to the delayed hypersensitivity reaction.

44 The immunological mechanisms driving delayed hypersensitivity reactions (HSRs) to drugs media

45 d in EPA and DHA suppressed antigen-specific delayed hypersensitivity reactions and mitogen-induced p

46 Currently, desensitization in delayed hypersensitivity reactions is restricted to mild

47 dies report a very low incidence of acute or delayed hypersensitivity reactions to the antivenom.

48 Delayed hypersensitivity reactions were not predictive o

49 The delayed hypersensitivity response to intradermal tubercu

50 Delayed hypersensitivity response to purified protein de

51 taneously in two doses 2 weeks apart, evoked delayed hypersensitivity responses in a concentration-de

52 Delayed hypersensitivity responses were not significantl

53 method for inducing tolerance in humoral and delayed hypersensitivity responses which is associated w

54 atients) and healthy control subjects with a delayed hypersensitivity skin test response to M. avium

55 ripheral T-cell function, as measured by the delayed hypersensitivity skin test to tuberculin, and an

56 Delayed hypersensitivity to IRBP was marginally reduced,

57 ere was a strong inverse association between delayed hypersensitivity to Mycobacterium tuberculosis a

58 ns and aztreonam in subjects with documented delayed hypersensitivity to penicillins who especially r

59 Donor-specific delayed hypersensitivity was not detected at 12 days, bu

60 We show that the delayed hypersensitivity was not mediated by either cell